EUVIMEDEUVIMED entdecken
Kohortenstudie

L26/P-412 Return to Conception and Reproductive Outcomes After Fertility Preservation (FP) in Young Women with Breast Cancer: A Long-Term Retrospective Cohort Study Including Pathogenic Variant Carriers

A. Finkelstein, A. Wertheimer, E. Altman, S. Danieli Gruber, A. Hochberg Amikam, T. Schohat, Y. Shufaro, A. Ben- Haroush, M. Sharon-Weiner

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.746 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Finkelstein und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question What are the long-term reproductive outcomes after FP and frozen embryo transfer (FET) in young women with breast cancer with or without a pathogenic variant? Summary answer FP enables meaningful long-term reproductive outcomes after breast cancer (BC); return-to-conception and FET were unaffected by estrogen receptor (ER) or pathogenic variant (PV). What is known already BC survival now exceeds 90%, and FP is widely recommended for young women prior to gonadotoxic therapy. Pregnancy after BC, including hormone receptor–positive disease, appears safe in selected patients. However, long-term data on return-to-conception, real-world utilization of cryopreserved oocytes or embryos, and FET outcomes after cancer treatment remain limited. Moreover, the impact of ER status and PV, including BRCA, on post-FP reproductive outcomes and timing of return-to-conception is incompletely understood, highlighting the need for long-term survivorship-focused reproductive data to better inform individualized counseling and clinical decision-making. Study design, size, duration Retrospective cohort study including young women with breast cancer undergoing FP between January 2005 and December 2023, with up to 18 years of follow-up. Long-term reproductive outcomes were analyzed in 148 patients with available post-treatment follow-up, enabling assessment of return-to-conception and live birth outcomes. Participants/materials, setting, methods Women aged 18–45 years referred for FP after BC diagnosis were included. FP consisted of oocyte and/or embryo cryopreservation ± ovarian function suppression (GnRHa). Attempts to conceive occurred naturally or via FET. Primary outcomes were clinical pregnancy and live birth. Secondary outcomes included return-to-conception rate, time from diagnosis, and use of cryopreserved material. ER and PV associations were assessed using chi-square or Fisher’s exact tests; competing risks were evaluated using Gray’s test. Main results and the role of chance A total of 148 women underwent FP to cryopreserve oocytes only or embryos (± oocytes). During the 18-year follow-up, 74/148 (50.0%) surviving patients returned to attempt conception by any method, and 35/74 (47.3%) returned first for fertility treatment using their cryopreserved oocytes/embryos. Among survivors who returned, the median time from breast cancer diagnosis to first conception attempt was 40.9 months, occurring earlier after embryo cryopreservation (± oocytes) than after oocyte-only cryopreservation (38.8 vs. 45.2 months). PV status was not associated with return to conception: among 140 patients with available BRCA data, return rates were similar between non-carriers (45/91, 49.5%) and carriers (24/49, 49.0%). ER status was likewise not associated with return to conception (n = 145), with comparable rates in ER-negative (34/69, 49.3%) and ER-positive patients (34/76, 44.7%). Patients who cryopreserved embryos (± oocytes) were more likely to return to conception compared with those who underwent oocyte cryopreservation alone (62.2% vs. 43.7%; p = 0.049). Clinical pregnancy per FP/FET occurred in 17/148 (11.5%). In competing risks analyses, cumulative incidence of return to conception did not differ by PV status (Gray’s test p = 0.8566) or ER expression (Gray’s test p = 0.5011); death before return to conception was treated as a competing risk. Limitations, reasons for caution Return-to-conception rates may reflect selection of highly motivated patients undergoing fertility preservation, the broad definition of return-to-conception (including spontaneous conception), and extended follow-up duration, which may limit generalizability to broader breast cancer populations. Wider implications of the findings Approximately half of breast cancer survivors returned to attempt conception over long-term follow-up, underscoring substantial real-world reproductive utilization after fertility preservation and supporting early oncofertility referral, timely counseling, and comprehensive survivorship care. Trial registration number No

Zitieren

APA

Finkelstein, A., Wertheimer, A., Altman, E., Gruber, S. D., Amikam, A. H., Schohat, T., Shufaro, Y., Haroush, A. B., & Sharon-Weiner, M. (2026). L26/P-412 Return to Conception and Reproductive Outcomes After Fertility Preservation (FP) in Young Women with Breast Cancer: A Long-Term Retrospective Cohort Study Including Pathogenic Variant Carriers. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.746

Vancouver

Finkelstein A, Wertheimer A, Altman E, Gruber SD, Amikam AH, Schohat T, et al. L26/P-412 Return to Conception and Reproductive Outcomes After Fertility Preservation (FP) in Young Women with Breast Cancer: A Long-Term Retrospective Cohort Study Including Pathogenic Variant Carriers. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.746

BibTeX
@article{Finkelstein2026,
  author = {Finkelstein, A. and Wertheimer, A. and Altman, E. and Gruber, S. Danieli and Amikam, A. Hochberg and Schohat, T. and Shufaro, Y. and Haroush, A. Ben- and Sharon-Weiner, M.},
  title = {L26/P-412 Return to Conception and Reproductive Outcomes After Fertility Preservation (FP) in Young Women with Breast Cancer: A Long-Term Retrospective Cohort Study Including Pathogenic Variant Carriers},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.746}
}
Kostenlos starten →